A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated 29 enrolled Eli Lilly and Company

Non-randomizedSequentialOpen-labelTreatment

Summary

Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.

Timeline

Start: 2010-03
Primary completion: 2011-06
Completion: 2011-06

Outcome

Outcome not reported

Stopped: “Primary objective has been met; safety and pharmacokinetics have been characterized.”

Publications

Hollebecque A, Houede N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar;50(5):876-84. doi: 10.1016/j.ejca.2013.12.006. Epub 2014 Jan 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	Everolimus	Small molecule	10 mg	Oral
Subject	LY2584702	Small molecule	50 mg	Oral
Subject	LY2584702	Small molecule	75 mg	Oral
Subject	LY2584702	Small molecule	100 mg	Oral